Comprehensive understanding of molecular principles in cancer and the diversification of oncological therapy promise individual therapeutic concepts, which have not yet found their way into urogenital cancer therapy. In March 2019 the International Society of Urogenital Pathology (ISUP) therefore held a consensus conference on recommendations for molecular diagnostics of genitourinary tumors, which were published in five separate manuscripts and are summarized in this article.In preparation for the conference, a comprehensive survey of current practices for molecular testing of urogenital tumors was carried out by members of the ISUP. At the conference, the results and the corresponding background information were presented by five working groups and recommendations for action for diagnostics were developed. An agreement between 66% of the conference participants was defined as consensus.

Das zunehmende Verständnis molekularer Grundlagen von Tumoren sowie der Fortschritt in der Diversifizierung der onkologischen Therapien versprechen individualisierte Therapieoptionen, welche bislang jedoch nur ansatzweise in die Therapieplanung von urologischen Tumoren eingegangen sind. Daher hat die Internationale Gesellschaft für Urologische Pathologie (ISUP) im März 2019 eine Konsenskonferenz zur Erarbeitung evidenzbasierter Handlungsempfehlungen zur molekularpathologischen Diagnostik beim Urothelkarzinom, Nierenzellkarzinom, Prostatakarzinom, Peniskarzinom und testikulären Keimzelltumoren durchgeführt. Die auf dieser Konsenskonferenz erarbeiteten Empfehlungen sind kürzlich in 5 separaten Manuskripten veröffentlich worden und werden in der vorliegenden Arbeit zusammengefasst.Im Rahmen der Konferenzvorbereitung wurde eine umfassende Umfrage zur derzeitigen Praxis molekularer Testungen bei urogenitalen Tumoren unter den Mitgliedern der ISUP durchgeführt. Auf der Konferenz wurden die Ergebnisse und die entsprechenden Hintergrundinformationen durch 5 Arbeitsgruppen präsentiert und Handlungsempfehlungen für die Diagnostik erarbeitet. Eine Übereinstimmung von 66 % der Konferenzteilnehmer wurde als Konsens definiert.

Cancer Diagnosis and Pathology Research Group Kolling Institute of Medical Research Royal North Shore Hospital St Leonards Australien

Department for Biomedical Research University of Bern and Bern Center for Precision Medicine Bern Schweiz

Department of Anatomical Pathology NSW Health Pathology Sidney Australien

Department of Laboratory Medicine University of Washington Seattle USA

Department of Oncology and Pathology Karolinska Institutet Stockholm Schweden

Department of Pathology and Laboratory Medicine and Henry Ford Cancer Institute Henry Ford Health System Detroit USA

Department of Pathology and Laboratory Medicine Indiana University School of Medicine Indianapolis USA

Department of Pathology and Laboratory Medicine University of Calgary Cumming School of Medicine and Alberta Public Labs Calgary Kanada

Department of Pathology Indiana University School of Medicine Indianapolis USA

Department of Pathology Institut Curie Saint Cloud Frankreich

Department of Pathology Johns Hopkins University School of Medicine Baltimore USA

Department of Pathology Memorial Sloan Kettering Cancer Center New York USA

Department of Pathology Penn State College of Medicine Hershey USA

Department of Pathology Stanford University School of Medicine Stanford USA

Department of Pathology Urology and Rogel Cancer Center University of Michigan Medical School Ann Arbor USA

Department of Pathology Wayne State University School of Medicine Detroit USA

Department of Scientific Research Norte University Asunción Paraguay

Departments of Pathology Oncology and Urology Johns Hopkins University Baltimore USA

Divison of Molecular Medicine Leeds Institute of Molecular Research at St James's St James's University Hospital Leeds Großbritannien

Inform Diagnostics and Tufts University Boston USA

Institut für Medizinische Genetik und Pathologie Universitätsspital Basel Basel Schweiz

Institut für Pathologie Universitätsklinikum Bonn Venusberg Campus 1 Gebäude 62 53127 Bonn Deutschland

Institut für Pathologie Universitätsklinikum Erlangen Friedrich Alexander Universität Erlangen Nürnberg Erlangen Deutschland

Laboratory Medicine Program University Health Network; Princess Margaret Cancer Centre University of Toronto Toronto Kanada

Medical Faculty and Charles University Hospital Plzen Charles University Pilsen Tschechien

Pathology and Research Institute and Medical Sciences of National University of Asuncion Asunción Paraguay

Pathology and Research Institute National University of Asuncion Asunción Paraguay

Pathology Indiana University School of Medicine Indianapolis USA

Princess Máxima Center for Pediatric Oncology Utrecht Niederlande

Sydney Medical School University of Sydney Sydney Australien

See more in PubMed

Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428–11436. PubMed PMC

Ahearn TU, Pettersson A, Ebot EM, et al. A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst. 2016;108(2):djv346. PubMed PMC

Al-Ahmadie HA, Iyer G, Lee BH, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48:356–358. PubMed PMC

Anderson CB, Lipsky M, Nandula SV, et al. Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations. Genes Chromosomes Cancer. 2019 doi: 10.1002/gcc.22766. PubMed DOI

Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038. PubMed PMC

Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019;75:378–382. PubMed PMC

Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103–113. PubMed

Azevedo R, Soares J, Peixoto A, et al. Circulating tumor cells in bladder cancer: emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol. 2018;36:221–236. PubMed

Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–1492. PubMed

Berlin A, Castro-Mesta JF, Rodriguez-Romo L, et al. Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2017;35:499–506. PubMed

Beukers W, Van Der Keur KA, Kandimalla R, et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol. 2017;197:1410–1418. PubMed

Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017 doi: 10.1200/PO.17.00073. PubMed DOI PMC

Brand TC, Zhang N, Crager MR, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene genomic prostate score. Urology. 2016;89:69–75. PubMed

Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32:1968–1976. PubMed PMC

Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79–86. PubMed

Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32:656–670. PubMed

Cancer Genome Atlas Research Network The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–1025. PubMed PMC

Canete-Portillo S, Velazquez EF, Kristiansen G, et al. Report from the international Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers V: recommendations on the use of immunohistochemical and molecular biomarkers in penile cancer. Am J Surg Pathol. 2020;44(7):e80–e86. PubMed

Cheng HH, Pritchard CC, Boyd T, et al. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol. 2016;69:992–995. PubMed PMC

Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547–1557. PubMed

Conteduca V, Wetterskog D, Sharabiani MTA, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28:1508–1516. PubMed PMC

Cubilla AL, Lloveras B, Alejo M, et al. Value of p16(INK)4(a) in the pathology of invasive penile squamous cell carcinomas: a report of 202 cases. Am J Surg Pathol. 2011;35:253–261. PubMed

Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106:1095–1099. PubMed PMC

Dunant N (2020) Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints. https://www.roche.com/media/releases/med-cor-2020-06-19.htm. Zugegriffen: 25. Okt. 2020

FDA (2020) FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer. Zugegriffen: 1. Juni 2020

Fernández-Nestosa MJ, Guimerà N, Sanchez DF, et al. Comparison of human papillomavirus genotypes in penile Intraepithelial neoplasia and associated lesions: LCM-PCR study of 87 lesions in 8 patients. Int J Surg Pathol. 2020;28:265–272. PubMed

Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2018;72:106–116. PubMed

Gobbo S, Eble JN, Delahunt B, et al. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profiles. Am J Surg Pathol. 2010;34:620–626. PubMed

Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–243. PubMed PMC

Guedes LB, Antonarakis ES, Schweizer MT, et al. MSH2 loss in primary prostate cancer. Clin Cancer Res. 2017;23:6863–6874. PubMed PMC

Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26:646–651. PubMed

Isharwal S, Hu W, Sarungbam J, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol. 2019;248:260–265. PubMed PMC

Isharwal S, Huang H, Nanjangud G, et al. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol. 2018;77:63–69. PubMed PMC

Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15:222–234. PubMed PMC

Jia L, Carlo MI, Khan H, et al. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. Mod Pathol. 2019;32:1329–1343. PubMed PMC

Kammerer-Jacquet SF, Ahmad A, Møller H, et al. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Mod Pathol. 2019;32:1303–1309. PubMed PMC

Kamoun A, De Reynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420–433. PubMed PMC

Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013;73:7162–7167. PubMed PMC

Krentz AD, Murphy MW, Kim S, et al. The DM domain protein DMRT1 is a dose-sensitive regulator of fetal germ cell proliferation and pluripotency. Proc Natl Acad Sci U S A. 2009;106:22323–22328. PubMed PMC

Lau HD, Chan E, Fan AC, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol. 2020;44:98–110. PubMed

Leapman MS, Nguyen HG, Cowan JE, et al. Comparing prognostic utility of a single-marker immunohistochemistry approach with commercial gene expression profiling following radical prostatectomy. Eur Urol. 2018;74:668–675. PubMed

Lokman U, Erickson AM, Vasarainen H, et al. PTEN loss but not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance. Eur Urol Focus. 2018;4:867–873. PubMed

Looijenga LHJ, Van Der Kwast TH, Grignon D, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. IV. Current and future utilization of molecular-genetic tests for testicular germ cell tumors. Am J Surg Pathol. 2020;44(7):e66–e79. doi: 10.1097/PAS.0000000000001465. PubMed DOI PMC

Lotan TL, Carvalho FL, Peskoe SB, et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 2015;28:128–137. PubMed PMC

Lotan TL, Tomlins SA, Bismar TA, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. I. Molecular biomarkers in prostate cancer. Am J Surg Pathol. 2020;44(7):e15–e29. doi: 10.1097/PAS.0000000000001450. PubMed DOI

Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753–3758. PubMed

Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313–1319. PubMed

Mithal P, Allott E, Gerber L, et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol. 2014;21:1209–1214. PubMed

Mostert M, Rosenberg C, Stoop H, et al. Comparative genomic and in situ hybridization of germ cell tumors of the infantile testis. Lab Invest. 2000;80:1055–1064. PubMed

Murray MJ, Coleman N. Testicular cancer: a new generation of biomarkers for malignant germ cell tumours. Nat Rev Urol. 2012;9:298–300. PubMed

Pal SK, Bergerot P, Dizman N, et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol. 2018;74:124–128. PubMed

Perlman EJ, Hu J, Ho D, et al. Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization. J Pediatr Hematol Oncol. 2000;22:100–105. PubMed

Piva F, Santoni M, Matrana MR, et al. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn. 2015;15:1201–1210. PubMed

Pomerantz MM, Spisak S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123:3532–3539. PubMed PMC

Reis H, Szarvas T. Therapieprädiktive Biomarker des Harnblasenkarzinoms. Pathologe. 2019;40:331–338. PubMed

Risbridger GP, Taylor RA, Clouston D, et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol. 2015;67:496–503. PubMed

Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e525. PubMed PMC

Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228. PubMed PMC

Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011;24:1207–1220. PubMed

Ross AE, Johnson MH, Yousefi K, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol. 2016;69:157–165. PubMed

Rouprêt M, Fromont G, Azzouzi AR, et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology. 2005;65:1233–1237. PubMed

Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73. PubMed

Schweizer MT, Antonarakis ES, Bismar TA, et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis Oncol. 2019 doi: 10.1200/PO.18.00327. PubMed DOI PMC

Seiler R, Al Deen Ashab H, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72:544–554. PubMed

Shuch B, Vourganti S, Ricketts CJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32:431–437. PubMed PMC

Sjodahl G, Abrahamsson J, Holmsten K, et al. Pathologic downstaging after neoadjuvant cisplatin-based combination chemotherapy in immunohistochemistry-defined molecular subtypes of bladder cancer. Eur Urol Suppl. 2019;18:e2106–e2107.

Sperga M, Martinek P, Vanecek T, et al. Chromophobe renal cell carcinoma—chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases. Virchows Arch. 2013;463:563–573. PubMed

Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol. 2012;25:1516–1525. PubMed

Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019;24:563–569. PubMed PMC

Thompson S, Cioffi-Lavina M, Chapman-Fredricks J, et al. Distinction of high-grade neuroendocrine carcinoma/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: an immunohistochemical approach. Appl Immunohistochem Mol Morphol. 2011;19:395–399. PubMed

Turney A (2019) FDA approves first targeted therapy for metastatic bladder cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer. Zugegriffen: 1. Juni 2020

Ulbright TM, Tickoo SK, Berney DM, et al. Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol. 2014;38:e50–e59. PubMed

Van Echten J, Oosterhuis JW, Looijenga LH, et al. No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chromosomes Cancer. 1995;14:133–144. PubMed

Van Kessel KEM, Van Der Keur KA, Dyrskjot L, et al. Molecular markers increase precision of the European association of urology non-muscle-invasive bladder cancer progression risk groups. Clin Cancer Res. 2018;24:1586–1593. PubMed

Velho PI, Lim D, Wang H, et al. Molecular characterization and clinical outcomes of primary Gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. 2019 doi: 10.1200/PO.19.00081. PubMed DOI PMC

Warrick JI, Knowles MA, Yves A, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. II. Molecular pathology of bladder cancer: progress and challenges. Am J Surg Pathol. 2020;44(7):e30–e46. doi: 10.1097/PAS.0000000000001453. PubMed DOI

Williamson SR, Gill AJ, Argani P, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. III. Molecular pathology of kidney cancer. Am J Surg Pathol. 2020;44(7):e47–e65. doi: 10.1097/PAS.0000000000001476. PubMed DOI PMC

Xu J, Reznik E, Lee HJ, et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife. 2019;8:e38986. PubMed PMC

Zhong M, Tian W, Zhuge J, et al. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol. 2015;39:127–131. PubMed